NTLA
Price
$8.29
Change
+$0.37 (+4.67%)
Updated
Apr 22, 04:59 PM (EDT)
Capitalization
748.43M
9 days until earnings call
RCKT
Price
$6.96
Change
-$0.21 (-2.93%)
Updated
Apr 22, 04:59 PM (EDT)
Capitalization
764.53M
20 days until earnings call
Ad is loading...

NTLA vs RCKT

Header iconNTLA vs RCKT Comparison
Open Charts NTLA vs RCKTBanner chart's image
Intellia Therapeutics
Price$8.29
Change+$0.37 (+4.67%)
Volume$45.73K
Capitalization748.43M
Rocket Pharmaceuticals
Price$6.96
Change-$0.21 (-2.93%)
Volume$69.05K
Capitalization764.53M
NTLA vs RCKT Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. RCKT commentary
Apr 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and RCKT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 22, 2025
Stock price -- (NTLA: $7.92 vs. RCKT: $7.17)
Brand notoriety: NTLA and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 150% vs. RCKT: 197%
Market capitalization -- NTLA: $748.43M vs. RCKT: $764.53M
NTLA [@Biotechnology] is valued at $748.43M. RCKT’s [@Biotechnology] market capitalization is $764.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $285.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, both NTLA and RCKT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • RCKT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NTLA and RCKT are a good buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а +5.60% price change this week, while RCKT (@Biotechnology) price change was +21.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.69%. For the same industry, the average monthly price growth was -9.18%, and the average quarterly price growth was -11.79%.

Reported Earning Dates

NTLA is expected to report earnings on Jul 31, 2025.

RCKT is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+5.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($765M) and NTLA($748M) have the same market capitalization . NTLA YTD gains are higher at: -32.075 vs. RCKT (-42.959). RCKT has higher annual earnings (EBITDA): -247.48M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. RCKT (372M). RCKT has less debt than NTLA: RCKT (25.5M) vs NTLA (210M). NTLA has higher revenues than RCKT: NTLA (57.9M) vs RCKT (0).
NTLARCKTNTLA / RCKT
Capitalization748M765M98%
EBITDA-523.98M-247.48M212%
Gain YTD-32.075-42.95975%
P/E RatioN/AN/A-
Revenue57.9M0-
Total Cash602M372M162%
Total Debt210M25.5M824%
FUNDAMENTALS RATINGS
NTLA vs RCKT: Fundamental Ratings
NTLA
RCKT
OUTLOOK RATING
1..100
6218
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9194
PRICE GROWTH RATING
1..100
9294
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is in the same range as RCKT (31). This means that NTLA’s stock grew similarly to RCKT’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RCKT (100). This means that NTLA’s stock grew similarly to RCKT’s over the last 12 months.

NTLA's SMR Rating (91) in the Biotechnology industry is in the same range as RCKT (94). This means that NTLA’s stock grew similarly to RCKT’s over the last 12 months.

NTLA's Price Growth Rating (92) in the Biotechnology industry is in the same range as RCKT (94). This means that NTLA’s stock grew similarly to RCKT’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RCKT (100). This means that NTLA’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLARCKT
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 19 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGDTX34.83N/A
N/A
Fidelity Advisor Gold M
SLCCX33.78N/A
N/A
ClearBridge Large Cap Growth C
PPIMX6.84N/A
N/A
Principal MidCap Growth III Inst
PVFAX44.73N/A
N/A
Paradigm Value
BGATX14.47-0.29
-1.96%
Baillie Gifford Global Alpha Equities 2